Viyash Scientific Limited announced its Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The Board also approved the adoption of a new set of Articles of Association and the grant of 1,30,98,000 stock options under the “Viyash Scientific Limited Employee Stock Option Scheme 2026”. Additionally, the Board decided not to recommend any dividend for the financial year 2025-26 to conserve resources.

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is a prominent player in the animal and human health segments of the pharmaceutical industry. The company maintains a diversified business profile with a significant presence in API, intermediates, and formulations, supported by strong research and development capabilities and a global reach spanning multiple continents.

The company’s financial performance shows positive momentum. For the quarter ended March 31, 2026, the company reported revenue from operations of ₹3,724.90 crore, compared to ₹3,416.40 crore in the preceding quarter (December 31, 2025) and ₹3,443.20 crore in the corresponding quarter of the previous year (March 31, 2025).